SIRT1 activators — methoxy groups change absorption, not certainty
What this is
Head-to-head evidence table: Trans-Resveratrol vs Pterostilbene (compound).
Why it matters
Resveratrol has longer human exposure history and SIRT1 literature. Pterostilbene is more lipophilic with longer half-life in preclinical models — human longevity outcomes for both remain Tier B.
What to do next
Use the verdict row to pick a primary compound, then open both deep-dives and /shop verification checklists.
Resveratrol has longer human exposure history and SIRT1 literature. Pterostilbene is more lipophilic with longer half-life in preclinical models — human longevity outcomes for both remain Tier B.
SIRT1 activation data
Trans-Resveratrol
Extensive in-vitro + human pilot exposure
Pterostilbene
Strong preclinical; fewer human trials
Oral bioavailability
Trans-Resveratrol
Low — needs fat + micronization
Pterostilbene
Higher lipophilicity in models
TNiC stack integration
Trans-Resveratrol
Native PM pair in SIRT1 preset
Pterostilbene
Manual substitution
Typical dose
Trans-Resveratrol
150–500 mg trans-resveratrol
Pterostilbene
50–150 mg pterostilbene
Evidence tier (longevity)
Trans-Resveratrol
Tier B
Pterostilbene
Tier B
Drug interactions
Trans-Resveratrol
CYP substrates — physician review
Pterostilbene
Similar CYP caution
TNiC verdict
Resveratrol wins for TNiC SIRT1 stack parity with published NMN pairings. Pterostilbene is experimental swap — only with NAD+ monitoring and physician awareness.
Choose Trans-Resveratrol when
Choose Pterostilbene when
Decided? Each verified pick matches the studied dose and form, and links straight to the manufacturer.
Links go to the manufacturer and may carry an affiliate token — at no extra cost to you. TNiC sells nothing and commission never moves a ranking or evidence tier. Educational information, not medical advice.